{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,19]],"date-time":"2026-07-19T03:07:19Z","timestamp":1784430439959,"version":"3.55.0"},"reference-count":142,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2017,10,16]],"date-time":"2017-10-16T00:00:00Z","timestamp":1508112000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Metastasis Rev"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1007\/s10555-017-9701-1","type":"journal-article","created":{"date-parts":[[2017,10,16]],"date-time":"2017-10-16T05:57:00Z","timestamp":1508133420000},"page":"655-668","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":51,"title":["Metal-based proteasomal deubiquitinase inhibitors as potential anticancer agents"],"prefix":"10.1007","volume":"36","author":[{"given":"Xin","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianqian","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daolin","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Q. Ping","family":"Dou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinbao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,10,16]]},"reference":[{"issue":"1","key":"9701_CR1","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1038\/cdd.2009.82","volume":"17","author":"AG Eldridge","year":"2010","unstructured":"Eldridge, A. G., & O'Brien, T. (2010). Therapeutic strategies within the ubiquitin proteasome system. Cell Death and Differentiation, 17(1), 4\u201313. https:\/\/doi.org\/10.1038\/cdd.2009.82 .","journal-title":"Cell Death and Differentiation"},{"issue":"3","key":"9701_CR2","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/S0968-0004(96)10012-8","volume":"21","author":"W Hilt","year":"1996","unstructured":"Hilt, W., & Wolf, D. H. (1996). Proteasomes: destruction as a programme. Trends in Biochemical Sciences, 21(3), 96\u2013102.","journal-title":"Trends in Biochemical Sciences"},{"issue":"13","key":"9701_CR3","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1007\/s00018-004-4129-5","volume":"61","author":"S Fang","year":"2004","unstructured":"Fang, S., & Weissman, A. M. (2004). A field guide to ubiquitylation. Cellular and Molecular Life Sciences, 61(13), 1546\u20131561. https:\/\/doi.org\/10.1007\/s00018-004-4129-5 .","journal-title":"Cellular and Molecular Life Sciences"},{"issue":"Suppl 1","key":"9701_CR4","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0305-7372(03)00081-1","volume":"29","author":"J Adams","year":"2003","unstructured":"Adams, J. (2003). The proteasome: structure, function, and role in the cell. Cancer Treatment Reviews, 29(Suppl 1), 3\u20139.","journal-title":"Cancer Treatment Reviews"},{"issue":"2","key":"9701_CR5","doi-asserted-by":"crossref","first-page":"124","DOI":"10.5732\/cjc.010.10162","volume":"30","author":"JH Drie Van","year":"2011","unstructured":"Van Drie, J. H. (2011). Protein folding, protein homeostasis, and cancer. Chinese Journal of Cancer, 30(2), 124\u2013137.","journal-title":"Chinese Journal of Cancer"},{"issue":"5","key":"9701_CR6","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/j.ccell.2015.10.002","volume":"28","author":"DJ Anderson","year":"2015","unstructured":"Anderson, D. J., Le Moigne, R., Djakovic, S., Kumar, B., Rice, J., Wong, S., et al. (2015). Targeting the AAA ATPase p97 as an approach to treat cancer through disruption of protein homeostasis. Cancer Cell, 28(5), 653\u2013665. https:\/\/doi.org\/10.1016\/j.ccell.2015.10.002 .","journal-title":"Cancer Cell"},{"issue":"2","key":"9701_CR7","doi-asserted-by":"publisher","first-page":"191","DOI":"10.2217\/14796694.3.2.191","volume":"3","author":"B Nicholson","year":"2007","unstructured":"Nicholson, B., Marblestone, J. G., Butt, T. R., & Mattern, M. R. (2007). Deubiquitinating enzymes as novel anticancer targets. Future Oncology, 3(2), 191\u2013199. https:\/\/doi.org\/10.2217\/14796694.3.2.191 .","journal-title":"Future Oncology"},{"issue":"12","key":"9701_CR8","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1038\/nm.2536","volume":"17","author":"P D'Arcy","year":"2011","unstructured":"D'Arcy, P., Brnjic, S., Olofsson, M. H., Fryknas, M., Lindsten, K., De Cesare, M., et al. (2011). Inhibition of proteasome deubiquitinating activity as a new cancer therapy. Nature Medicine, 17(12), 1636\u20131640. https:\/\/doi.org\/10.1038\/nm.2536 .","journal-title":"Nature Medicine"},{"issue":"20","key":"9701_CR9","doi-asserted-by":"publisher","first-page":"6256","DOI":"10.1021\/jm8007807","volume":"51","author":"B Cvek","year":"2008","unstructured":"Cvek, B., Milacic, V., Taraba, J., & Dou, Q. P. (2008). Ni(II), Cu(II), and Zn(II) diethyldithiocarbamate complexes show various activities against the proteasome in breast cancer cells. Journal of Medicinal Chemistry, 51(20), 6256\u20136258. https:\/\/doi.org\/10.1021\/jm8007807 .","journal-title":"Journal of Medicinal Chemistry"},{"key":"9701_CR10","doi-asserted-by":"crossref","first-page":"375","DOI":"10.2741\/s274","volume":"4","author":"SM Schmitt","year":"2012","unstructured":"Schmitt, S. M., Frezza, M., & Dou, Q. P. (2012). New applications of old metal-binding drugs in the treatment of human cancer. Frontiers in Bioscience (Scholar Edition), 4, 375\u2013391.","journal-title":"Frontiers in Bioscience (Scholar Edition)"},{"issue":"5","key":"9701_CR11","doi-asserted-by":"publisher","first-page":"457","DOI":"10.18632\/oncoscience.167","volume":"2","author":"N Liu","year":"2015","unstructured":"Liu, N., Huang, H., Dou, Q. P., & Liu, J. (2015). Inhibition of 19S proteasome-associated deubiquitinases by metal-containing compounds. Oncoscience, 2(5), 457\u2013466. 10.18632\/oncoscience.167 .","journal-title":"Oncoscience"},{"issue":"45","key":"9701_CR12","doi-asserted-by":"publisher","first-page":"5153","DOI":"10.1039\/c3cc41766b","volume":"49","author":"JJ Zhang","year":"2013","unstructured":"Zhang, J. J., Ng, K. M., Lok, C. N., Sun, R. W., & Che, C. M. (2013). Deubiquitinases as potential anti-cancer targets for gold(III) complexes. Chem Commun (Camb), 49(45), 5153\u20135155. https:\/\/doi.org\/10.1039\/c3cc41766b .","journal-title":"Chem Commun (Camb)"},{"issue":"19","key":"9701_CR13","doi-asserted-by":"publisher","first-page":"2373","DOI":"10.1038\/onc.2011.443","volume":"31","author":"JM Fraile","year":"2012","unstructured":"Fraile, J. M., Quesada, V., Rodriguez, D., Freije, J. M., & Lopez-Otin, C. (2012). Deubiquitinases in cancer: new functions and therapeutic options. Oncogene, 31(19), 2373\u20132388. https:\/\/doi.org\/10.1038\/onc.2011.443 .","journal-title":"Oncogene"},{"key":"9701_CR14","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.pharmthera.2014.11.002","volume":"147","author":"P D'Arcy","year":"2015","unstructured":"D'Arcy, P., Wang, X., & Linder, S. (2015). Deubiquitinase inhibition as a cancer therapeutic strategy. Pharmacology & Therapeutics, 147, 32\u201354. https:\/\/doi.org\/10.1016\/j.pharmthera.2014.11.002 .","journal-title":"Pharmacology & Therapeutics"},{"issue":"18","key":"9701_CR15","doi-asserted-by":"publisher","first-page":"5187","DOI":"10.1093\/emboj\/20.18.5187","volume":"20","author":"A Borodovsky","year":"2001","unstructured":"Borodovsky, A., Kessler, B. M., Casagrande, R., Overkleeft, H. S., Wilkinson, K. D., & Ploegh, H. L. (2001). A novel active site-directed probe specific for deubiquitylating enzymes reveals proteasome association of USP14. The EMBO Journal, 20(18), 5187\u20135196. https:\/\/doi.org\/10.1093\/emboj\/20.18.5187 .","journal-title":"The EMBO Journal"},{"issue":"7","key":"9701_CR16","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/S0092-8674(02)01199-6","volume":"111","author":"M Hu","year":"2002","unstructured":"Hu, M., Li, P., Li, M., Li, W., Yao, T., Wu, J. W., et al. (2002). Crystal structure of a UBP-family deubiquitinating enzyme in isolation and in complex with ubiquitin aldehyde. Cell, 111(7), 1041\u20131054.","journal-title":"Cell"},{"issue":"11","key":"9701_CR17","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1038\/nchembio.2007.43","volume":"3","author":"KR Love","year":"2007","unstructured":"Love, K. R., Catic, A., Schlieker, C., & Ploegh, H. L. (2007). Mechanisms, biology and inhibitors of deubiquitinating enzymes. Nature Chemical Biology, 3(11), 697\u2013705. https:\/\/doi.org\/10.1038\/nchembio.2007.43 .","journal-title":"Nature Chemical Biology"},{"issue":"9","key":"9701_CR18","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/j.chembiol.2003.08.010","volume":"10","author":"Y Liu","year":"2003","unstructured":"Liu, Y., Lashuel, H. A., Choi, S., Xing, X., Case, A., Ni, J., et al. (2003). Discovery of inhibitors that elucidate the role of UCH-L1 activity in the H1299 lung cancer cell line. Chemistry & Biology, 10(9), 837\u2013846.","journal-title":"Chemistry & Biology"},{"issue":"4","key":"9701_CR19","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1016\/j.bbrc.2004.05.098","volume":"319","author":"Z Li","year":"2004","unstructured":"Li, Z., Melandri, F., Berdo, I., Jansen, M., Hunter, L., Wright, S., et al. (2004). Delta12-Prostaglandin J2 inhibits the ubiquitin hydrolase UCH-L1 and elicits ubiquitin-protein aggregation without proteasome inhibition. Biochemical and Biophysical Research Communications, 319(4), 1171\u20131180. https:\/\/doi.org\/10.1016\/j.bbrc.2004.05.098 .","journal-title":"Biochemical and Biophysical Research Communications"},{"issue":"2","key":"9701_CR20","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.nbd.2010.09.020","volume":"41","author":"H Liu","year":"2011","unstructured":"Liu, H., Li, W., Ahmad, M., Miller, T. M., Rose, M. E., Poloyac, S. M., et al. (2011). Modification of ubiquitin-C-terminal hydrolase-L1 by cyclopentenone prostaglandins exacerbates hypoxic injury. Neurobiology of Disease, 41(2), 318\u2013328. https:\/\/doi.org\/10.1016\/j.nbd.2010.09.020 .","journal-title":"Neurobiology of Disease"},{"issue":"11","key":"9701_CR21","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1016\/j.chembiol.2011.08.014","volume":"18","author":"J Chen","year":"2011","unstructured":"Chen, J., Dexheimer, T. S., Ai, Y., Liang, Q., Villamil, M. A., Inglese, J., et al. (2011). Selective and cell-active inhibitors of the USP1\/ UAF1 deubiquitinase complex reverse cisplatin resistance in non-small cell lung cancer cells. Chemistry & Biology, 18(11), 1390\u20131400. https:\/\/doi.org\/10.1016\/j.chembiol.2011.08.014 .","journal-title":"Chemistry & Biology"},{"issue":"12","key":"9701_CR22","doi-asserted-by":"publisher","first-page":"2651","DOI":"10.1158\/1535-7163.MCT-13-0103-T","volume":"12","author":"H Mistry","year":"2013","unstructured":"Mistry, H., Hsieh, G., Buhrlage, S. J., Huang, M., Park, E., Cuny, G. D., et al. (2013). Small-molecule inhibitors of USP1 target ID1 degradation in leukemic cells. Molecular Cancer Therapeutics, 12(12), 2651\u20132662. https:\/\/doi.org\/10.1158\/1535-7163.MCT-13-0103-T .","journal-title":"Molecular Cancer Therapeutics"},{"issue":"8","key":"9701_CR23","doi-asserted-by":"publisher","first-page":"2286","DOI":"10.1158\/1535-7163.MCT-09-0097","volume":"8","author":"F Colland","year":"2009","unstructured":"Colland, F., Formstecher, E., Jacq, X., Reverdy, C., Planquette, C., Conrath, S., et al. (2009). Small-molecule inhibitor of USP7\/HAUSP ubiquitin protease stabilizes and activates p53 in cells. Molecular Cancer Therapeutics, 8(8), 2286\u20132295. https:\/\/doi.org\/10.1158\/1535-7163.MCT-09-0097 .","journal-title":"Molecular Cancer Therapeutics"},{"issue":"2","key":"9701_CR24","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1089\/adt.2010.0317","volume":"9","author":"X Tian","year":"2011","unstructured":"Tian, X., Isamiddinova, N. S., Peroutka, R. J., Goldenberg, S. J., Mattern, M. R., Nicholson, B., et al. (2011). Characterization of selective ubiquitin and ubiquitin-like protease inhibitors using a fluorescence-based multiplex assay format. Assay and Drug Development Technologies, 9(2), 165\u2013173. https:\/\/doi.org\/10.1089\/adt.2010.0317 .","journal-title":"Assay and Drug Development Technologies"},{"issue":"4","key":"9701_CR25","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/j.chembiol.2012.02.007","volume":"19","author":"C Reverdy","year":"2012","unstructured":"Reverdy, C., Conrath, S., Lopez, R., Planquette, C., Atmanene, C., Collura, V., et al. (2012). Discovery of specific inhibitors of human USP7\/HAUSP deubiquitinating enzyme. Chemistry & Biology, 19(4), 467\u2013477. https:\/\/doi.org\/10.1016\/j.chembiol.2012.02.007 .","journal-title":"Chemistry & Biology"},{"issue":"3","key":"9701_CR26","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.ccr.2012.08.007","volume":"22","author":"D Chauhan","year":"2012","unstructured":"Chauhan, D., Tian, Z., Nicholson, B., Kumar, K. G., Zhou, B., Carrasco, R., et al. (2012). A small molecule inhibitor of ubiquitin-specific protease-7 induces apoptosis in multiple myeloma cells and overcomes bortezomib resistance. Cancer Cell, 22(3), 345\u2013358. https:\/\/doi.org\/10.1016\/j.ccr.2012.08.007 .","journal-title":"Cancer Cell"},{"issue":"2","key":"9701_CR27","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.biochi.2007.09.013","volume":"90","author":"L Daviet","year":"2008","unstructured":"Daviet, L., & Colland, F. (2008). Targeting ubiquitin specific proteases for drug discovery. Biochimie, 90(2), 270\u2013283. https:\/\/doi.org\/10.1016\/j.biochi.2007.09.013 .","journal-title":"Biochimie"},{"issue":"4","key":"9701_CR28","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1002\/cmdc.200900409","volume":"5","author":"M Colombo","year":"2010","unstructured":"Colombo, M., Vallese, S., Peretto, I., Jacq, X., Rain, J. C., Colland, F., et al. (2010). Synthesis and biological evaluation of 9-oxo-9H-indeno[1,2-b]pyrazine-2,3-dicarbonitrile analogues as potential inhibitors of deubiquitinating enzymes. ChemMedChem, 5(4), 552\u2013558. https:\/\/doi.org\/10.1002\/cmdc.200900409 .","journal-title":"ChemMedChem"},{"issue":"3","key":"9701_CR29","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/S1097-2765(02)00638-X","volume":"10","author":"DS Leggett","year":"2002","unstructured":"Leggett, D. S., Hanna, J., Borodovsky, A., Crosas, B., Schmidt, M., Baker, R. T., et al. (2002). Multiple associated proteins regulate proteasome structure and function. Molecular Cell, 10(3), 495\u2013507.","journal-title":"Molecular Cell"},{"issue":"24","key":"9701_CR30","doi-asserted-by":"publisher","first-page":"5742","DOI":"10.1038\/sj.emboj.7601450","volume":"25","author":"XB Qiu","year":"2006","unstructured":"Qiu, X. B., Ouyang, S. Y., Li, C. J., Miao, S., Wang, L., & Goldberg, A. L. (2006). hRpn13\/ADRM1\/GP110 is a novel proteasome subunit that binds the deubiquitinating enzyme, UCH37. The EMBO Journal, 25(24), 5742\u20135753. https:\/\/doi.org\/10.1038\/sj.emboj.7601450 .","journal-title":"The EMBO Journal"},{"issue":"3","key":"9701_CR31","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1016\/j.jmb.2004.09.057","volume":"344","author":"M Stone","year":"2004","unstructured":"Stone, M., Hartmann-Petersen, R., Seeger, M., Bech-Otschir, D., Wallace, M., & Gordon, C. (2004). Uch2\/Uch37 is the major deubiquitinating enzyme associated with the 26S proteasome in fission yeast. Journal of Molecular Biology, 344(3), 697\u2013706. https:\/\/doi.org\/10.1016\/j.jmb.2004.09.057 .","journal-title":"Journal of Molecular Biology"},{"issue":"6905","key":"9701_CR32","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1038\/nature01071","volume":"419","author":"T Yao","year":"2002","unstructured":"Yao, T., & Cohen, R. E. (2002). A cryptic protease couples deubiquitination and degradation by the proteasome. Nature, 419(6905), 403\u2013407. https:\/\/doi.org\/10.1038\/nature01071 .","journal-title":"Nature"},{"issue":"5593","key":"9701_CR33","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1126\/science.1075898","volume":"298","author":"R Verma","year":"2002","unstructured":"Verma, R., Aravind, L., Oania, R., McDonald, W. H., Yates 3rd, J. R., Koonin, E. V., et al. (2002). Role of Rpn11 metalloprotease in deubiquitination and degradation by the 26S proteasome. Science, 298(5593), 611\u2013615. https:\/\/doi.org\/10.1126\/science.1075898 .","journal-title":"Science"},{"issue":"6618","key":"9701_CR34","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1038\/385737a0","volume":"385","author":"YA Lam","year":"1997","unstructured":"Lam, Y. A., Xu, W., DeMartino, G. N., & Cohen, R. E. (1997). Editing of ubiquitin conjugates by an isopeptidase in the 26S proteasome. Nature, 385(6618), 737\u2013740. https:\/\/doi.org\/10.1038\/385737a0 .","journal-title":"Nature"},{"issue":"11","key":"9701_CR35","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1016\/j.biocel.2012.07.011","volume":"44","author":"P D'Arcy","year":"2012","unstructured":"D'Arcy, P., & Linder, S. (2012). Proteasome deubiquitinases as novel targets for cancer therapy. The International Journal of Biochemistry & Cell Biology, 44(11), 1729\u20131738. https:\/\/doi.org\/10.1016\/j.biocel.2012.07.011 .","journal-title":"The International Journal of Biochemistry & Cell Biology"},{"issue":"3","key":"9701_CR36","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1091\/mbc.E07-10-1040","volume":"19","author":"E Koulich","year":"2008","unstructured":"Koulich, E., Li, X., & DeMartino, G. N. (2008). Relative structural and functional roles of multiple deubiquitylating proteins associated with mammalian 26S proteasome. Molecular Biology of the Cell, 19(3), 1072\u20131082. https:\/\/doi.org\/10.1091\/mbc.E07-10-1040 .","journal-title":"Molecular Biology of the Cell"},{"issue":"1","key":"9701_CR37","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1158\/1535-7163.MCT-06-0542","volume":"6","author":"M Gallery","year":"2007","unstructured":"Gallery, M., Blank, J. L., Lin, Y., Gutierrez, J. A., Pulido, J. C., Rappoli, D., et al. (2007). The JAMM motif of human deubiquitinase Poh1 is essential for cell viability. Molecular Cancer Therapeutics, 6(1), 262\u2013268. https:\/\/doi.org\/10.1158\/1535-7163.MCT-06-0542 .","journal-title":"Molecular Cancer Therapeutics"},{"issue":"10","key":"9701_CR38","doi-asserted-by":"crossref","first-page":"2917","DOI":"10.1091\/mbc.9.10.2917","volume":"9","author":"T Rinaldi","year":"1998","unstructured":"Rinaldi, T., Ricci, C., Porro, D., Bolotin-Fukuhara, M., & Frontali, L. (1998). A mutation in a novel yeast proteasomal gene, RPN11\/MPR1, produces a cell cycle arrest, overreplication of nuclear and mitochondrial DNA, and an altered mitochondrial morphology. Molecular Biology of the Cell, 9(10), 2917\u20132931.","journal-title":"Molecular Biology of the Cell"},{"issue":"6C","key":"9701_CR39","first-page":"3905","volume":"22","author":"V Spataro","year":"2002","unstructured":"Spataro, V., Simmen, K., & Realini, C. A. (2002). The essential 26S proteasome subunit Rpn11 confers multidrug resistance to mammalian cells. Anticancer Research, 22(6C), 3905\u20133909.","journal-title":"Anticancer Research"},{"issue":"23","key":"9701_CR40","doi-asserted-by":"publisher","first-page":"16099","DOI":"10.1074\/jbc.M512086200","volume":"281","author":"JF Nabhan","year":"2006","unstructured":"Nabhan, J. F., & Ribeiro, P. (2006). The 19 S proteasomal subunit POH1 contributes to the regulation of c-Jun ubiquitination, stability, and subcellular localization. The Journal of Biological Chemistry, 281(23), 16099\u201316107. https:\/\/doi.org\/10.1074\/jbc.M512086200 .","journal-title":"The Journal of Biological Chemistry"},{"issue":"23","key":"9701_CR41","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1182\/blood.V126.23.1811.1811","volume":"126","author":"Y Song","year":"2015","unstructured":"Song, Y., Ray, A., DAS, D. S., Chauhan, D., & Anderson, K. C. (2015). Targeting 19S-proteasome deubiquitinase Rpn11\/POH1\/PSMD14 in multiple myeloma. Blood, 126(23), 1811\u20131811.","journal-title":"Blood"},{"issue":"54","key":"9701_CR42","doi-asserted-by":"publisher","first-page":"8080","DOI":"10.1038\/sj.onc.1208944","volume":"24","author":"SJ Wicks","year":"2005","unstructured":"Wicks, S. J., Haros, K., Maillard, M., Song, L., Cohen, R. E., Dijke, P. T., et al. (2005). The deubiquitinating enzyme UCH37 interacts with Smads and regulates TGF-beta signalling. Oncogene, 24(54), 8080\u20138084. https:\/\/doi.org\/10.1038\/sj.onc.1208944 .","journal-title":"Oncogene"},{"issue":"2","key":"9701_CR43","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.abb.2013.03.003","volume":"535","author":"YM Ko","year":"2013","unstructured":"Ko, Y. M., Chang, C. Y., Chiou, S. J., Hsu, F. J., Huang, J. S., Yang, Y. L., et al. (2013). Ubiquitin C-terminal hydrolase-L5 is required for high glucose-induced transforming growth factor-beta receptor I expression and hypertrophy in mesangial cells. Archives of Biochemistry and Biophysics, 535(2), 177\u2013186. https:\/\/doi.org\/10.1016\/j.abb.2013.03.003 .","journal-title":"Archives of Biochemistry and Biophysics"},{"issue":"3","key":"9701_CR44","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/j.bbamcr.2012.11.020","volume":"1833","author":"Y Fang","year":"2013","unstructured":"Fang, Y., Fu, D., Tang, W., Cai, Y., Ma, D., Wang, H., et al. (2013). Ubiquitin C-terminal Hydrolase 37, a novel predictor for hepatocellular carcinoma recurrence, promotes cell migration and invasion via interacting and deubiquitinating PRP19. Biochimica et Biophysica Acta, 1833(3), 559\u2013572. https:\/\/doi.org\/10.1016\/j.bbamcr.2012.11.020 .","journal-title":"Biochimica et Biophysica Acta"},{"issue":"2","key":"9701_CR45","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1002\/cbf.1734","volume":"29","author":"Z Chen","year":"2011","unstructured":"Chen, Z., Niu, X., Li, Z., Yu, Y., Ye, X., Lu, S., et al. (2011). Effect of ubiquitin carboxy-terminal hydrolase 37 on apoptotic in A549 cells. Cell Biochemistry and Function, 29(2), 142\u2013148. https:\/\/doi.org\/10.1002\/cbf.1734 .","journal-title":"Cell Biochemistry and Function"},{"issue":"7312","key":"9701_CR46","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1038\/nature09299","volume":"467","author":"BH Lee","year":"2010","unstructured":"Lee, B. H., Lee, M. J., Park, S., Oh, D. C., Elsasser, S., Chen, P. C., et al. (2010). Enhancement of proteasome activity by a small-molecule inhibitor of USP14. Nature, 467(7312), 179\u2013184. https:\/\/doi.org\/10.1038\/nature09299 .","journal-title":"Nature"},{"issue":"10","key":"9701_CR47","doi-asserted-by":"publisher","first-page":"e47884","DOI":"10.1371\/journal.pone.0047884","volume":"7","author":"YN Jin","year":"2012","unstructured":"Jin, Y. N., Chen, P. C., Watson, J. A., Walters, B. J., Phillips, S. E., Green, K., et al. (2012). Usp14 deficiency increases tau phosphorylation without altering tau degradation or causing tau-dependent deficits. PLoS One, 7(10), e47884. https:\/\/doi.org\/10.1371\/journal.pone.0047884 .","journal-title":"PLoS One"},{"key":"9701_CR48","doi-asserted-by":"publisher","first-page":"e64","DOI":"10.1038\/oncsis.2013.28","volume":"2","author":"H Jung","year":"2013","unstructured":"Jung, H., Kim, B. G., Han, W. H., Lee, J. H., Cho, J. Y., Park, W. S., et al. (2013). Deubiquitination of Dishevelled by Usp14 is required for Wnt signaling. Oncogene, 2, e64. https:\/\/doi.org\/10.1038\/oncsis.2013.28 .","journal-title":"Oncogene"},{"issue":"6","key":"9701_CR49","doi-asserted-by":"publisher","first-page":"10749","DOI":"10.3390\/ijms140610749","volume":"14","author":"N Wu","year":"2013","unstructured":"Wu, N., Liu, C., Bai, C., Han, Y. P., Cho, W. C., & Li, Q. (2013). Over-expression of deubiquitinating enzyme USP14 in lung adenocarcinoma promotes proliferation through the accumulation of beta-catenin. International Journal of Molecular Sciences, 14(6), 10749\u201310760. https:\/\/doi.org\/10.3390\/ijms140610749 .","journal-title":"International Journal of Molecular Sciences"},{"issue":"22","key":"9701_CR50","doi-asserted-by":"publisher","first-page":"15437","DOI":"10.1074\/jbc.C112.446682","volume":"288","author":"RK Mialki","year":"2013","unstructured":"Mialki, R. K., Zhao, J., Wei, J., Mallampalli, D. F., & Zhao, Y. (2013). Overexpression of USP14 protease reduces I-kappaB protein levels and increases cytokine release in lung epithelial cells. The Journal of Biological Chemistry, 288(22), 15437\u201315441. https:\/\/doi.org\/10.1074\/jbc.C112.446682 .","journal-title":"The Journal of Biological Chemistry"},{"key":"9701_CR51","doi-asserted-by":"publisher","first-page":"e10510","DOI":"10.7554\/eLife.10510","volume":"4","author":"D Xu","year":"2015","unstructured":"Xu, D., Shan, B., Lee, B. H., Zhu, K., Zhang, T., Sun, H., et al. (2015). Phosphorylation and activation of ubiquitin-specific protease-14 by Akt regulates the ubiquitin-proteasome system. eLife, 4, e10510. https:\/\/doi.org\/10.7554\/eLife.10510 .","journal-title":"eLife"},{"issue":"2","key":"9701_CR52","doi-asserted-by":"publisher","first-page":"e2585","DOI":"10.1038\/cddis.2016.477","volume":"8","author":"Y Liao","year":"2017","unstructured":"Liao, Y., Liu, N., Hua, X., Cai, J., Xia, X., Wang, X., et al. (2017). Proteasome-associated deubiquitinase ubiquitin-specific protease 14 regulates prostate cancer proliferation by deubiquitinating and stabilizing androgen receptor. Cell Death & Disease, 8(2), e2585. https:\/\/doi.org\/10.1038\/cddis.2016.477 .","journal-title":"Cell Death & Disease"},{"key":"9701_CR53","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/j.biocel.2016.08.038","volume":"79","author":"X Chen","year":"2016","unstructured":"Chen, X., Wu, J., Chen, Y., Ye, D., Lei, H., Xu, H., et al. (2016). Ubiquitin-specific protease 14 regulates cell proliferation and apoptosis in oral squamous cell carcinoma. The International Journal of Biochemistry & Cell Biology, 79, 350\u2013359. https:\/\/doi.org\/10.1016\/j.biocel.2016.08.038 .","journal-title":"The International Journal of Biochemistry & Cell Biology"},{"issue":"1","key":"9701_CR54","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1007\/s12032-014-0379-8","volume":"32","author":"Y Wang","year":"2015","unstructured":"Wang, Y., Wang, J., Zhong, J., Deng, Y., Xi, Q., He, S., et al. (2015). Ubiquitin-specific protease 14 (USP14) regulates cellular proliferation and apoptosis in epithelial ovarian cancer. Medical Oncology, 32(1), 379. https:\/\/doi.org\/10.1007\/s12032-014-0379-8 .","journal-title":"Medical Oncology"},{"issue":"3","key":"9701_CR55","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1159\/000443051","volume":"38","author":"Y Zhu","year":"2016","unstructured":"Zhu, Y., Zhang, C., Gu, C., Li, Q., & Wu, N. (2016). Function of deubiquitinating enzyme USP14 as oncogene in different types of cancer. Cellular Physiology and Biochemistry, 38(3), 993\u20131002. https:\/\/doi.org\/10.1159\/000443051 .","journal-title":"Cellular Physiology and Biochemistry"},{"issue":"1","key":"9701_CR56","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1111\/ejh.12729","volume":"98","author":"X Xu","year":"2017","unstructured":"Xu, X., Liu, J., Shen, C., Ding, L., Zhong, F., Ouyang, Y., et al. (2017). The role of ubiquitin-specific protease 14 (USP14) in cell adhesion-mediated drug resistance (CAM-DR) of multiple myeloma cells. European Journal of Haematology, 98(1), 4\u201312. https:\/\/doi.org\/10.1111\/ejh.12729 .","journal-title":"European Journal of Haematology"},{"issue":"1","key":"9701_CR57","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/0009-2797(78)90042-X","volume":"23","author":"TL Ho","year":"1978","unstructured":"Ho, T. L., Ho, H. C., & Hamilton, L. D. (1978). Biochemical significance of the hard and soft acids and bases principle. Chemico-Biological Interactions, 23(1), 65\u201384.","journal-title":"Chemico-Biological Interactions"},{"issue":"2","key":"9701_CR58","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1021\/tx2003257","volume":"25","author":"RM Lopachin","year":"2012","unstructured":"Lopachin, R. M., Gavin, T., Decaprio, A., & Barber, D. S. (2012). Application of the hard and soft, acids and bases (HSAB) theory to toxicant--target interactions. Chemical Research in Toxicology, 25(2), 239\u2013251. https:\/\/doi.org\/10.1021\/tx2003257 .","journal-title":"Chemical Research in Toxicology"},{"issue":"22","key":"9701_CR59","doi-asserted-by":"publisher","first-page":"9265","DOI":"10.1158\/0008-5472.CAN-10-1530","volume":"70","author":"V Kapuria","year":"2010","unstructured":"Kapuria, V., Peterson, L. F., Fang, D., Bornmann, W. G., Talpaz, M., & Donato, N. J. (2010). Deubiquitinase inhibition by small-molecule WP1130 triggers aggresome formation and tumor cell apoptosis. Cancer Research, 70(22), 9265\u20139276. https:\/\/doi.org\/10.1158\/0008-5472.CAN-10-1530 .","journal-title":"Cancer Research"},{"key":"9701_CR60","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1186\/1471-2407-12-541","volume":"12","author":"C Peddaboina","year":"2012","unstructured":"Peddaboina, C., Jupiter, D., Fletcher, S., Yap, J. L., Rai, A., Tobin, R. P., et al. (2012). The downregulation of Mcl-1 via USP9X inhibition sensitizes solid tumors to Bcl-xl inhibition. BMC Cancer, 12, 541. https:\/\/doi.org\/10.1186\/1471-2407-12-541 .","journal-title":"BMC Cancer"},{"issue":"11","key":"9701_CR61","doi-asserted-by":"publisher","first-page":"3151","DOI":"10.1182\/blood-2010-03-276477","volume":"117","author":"H Sun","year":"2011","unstructured":"Sun, H., Kapuria, V., Peterson, L. F., Fang, D., Bornmann, W. G., Bartholomeusz, G., et al. (2011). Bcr-Abl ubiquitination and Usp9x inhibition block kinase signaling and promote CML cell apoptosis. Blood, 117(11), 3151\u20133162. https:\/\/doi.org\/10.1182\/blood-2010-03-276477 .","journal-title":"Blood"},{"issue":"12","key":"9701_CR62","doi-asserted-by":"publisher","first-page":"2076","DOI":"10.1016\/j.cellsig.2011.08.002","volume":"23","author":"V Kapuria","year":"2011","unstructured":"Kapuria, V., Levitzki, A., Bornmann, W. G., Maxwell, D., Priebe, W., Sorenson, R. J., et al. (2011). A novel small molecule deubiquitinase inhibitor blocks Jak2 signaling through Jak2 ubiquitination. Cellular Signalling, 23(12), 2076\u20132085. https:\/\/doi.org\/10.1016\/j.cellsig.2011.08.002 .","journal-title":"Cellular Signalling"},{"issue":"9","key":"9701_CR63","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1080\/15548627.2015.1067359","volume":"11","author":"S Driessen","year":"2015","unstructured":"Driessen, S., Berleth, N., Friesen, O., Loffler, A. S., Bohler, P., Hieke, N., et al. (2015). Deubiquitinase inhibition by WP1130 leads to ULK1 aggregation and blockade of autophagy. Autophagy, 11(9), 1458\u20131470. https:\/\/doi.org\/10.1080\/15548627.2015.1067359 .","journal-title":"Autophagy"},{"issue":"7","key":"9701_CR64","doi-asserted-by":"publisher","first-page":"2026","DOI":"10.1158\/1535-7163.MCT-10-0238","volume":"9","author":"LV Pham","year":"2010","unstructured":"Pham, L. V., Tamayo, A. T., Li, C., Bornmann, W., Priebe, W., & Ford, R. J. (2010). Degrasyn potentiates the antitumor effects of bortezomib in mantle cell lymphoma cells in vitro and in vivo: therapeutic implications. Molecular Cancer Therapeutics, 9(7), 2026\u20132036. https:\/\/doi.org\/10.1158\/1535-7163.MCT-10-0238 .","journal-title":"Molecular Cancer Therapeutics"},{"issue":"4","key":"9701_CR65","first-page":"1783","volume":"9","author":"P Fu","year":"2017","unstructured":"Fu, P., Du, F., Liu, Y., Yao, M., Zhang, S., Zheng, X., et al. (2017). WP1130 increases cisplatin sensitivity through inhibition of usp9x in estrogen receptor-negative breast cancer cells. American Journal of Translational Research, 9(4), 1783\u20131791.","journal-title":"American Journal of Translational Research"},{"issue":"2","key":"9701_CR66","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/j.canlet.2015.03.001","volume":"361","author":"H Liu","year":"2015","unstructured":"Liu, H., Chen, W., Liang, C., Chen, B. W., Zhi, X., Zhang, S., et al. (2015). WP1130 increases doxorubicin sensitivity in hepatocellular carcinoma cells through usp9x-dependent p53 degradation. Cancer Letters, 361(2), 218\u2013225. https:\/\/doi.org\/10.1016\/j.canlet.2015.03.001 .","journal-title":"Cancer Letters"},{"issue":"18","key":"9701_CR67","doi-asserted-by":"publisher","first-page":"2081","DOI":"10.1016\/j.lfs.2005.12.007","volume":"78","author":"RK Maheshwari","year":"2006","unstructured":"Maheshwari, R. K., Singh, A. K., Gaddipati, J., & Srimal, R. C. (2006). Multiple biological activities of curcumin: a short review. Life Sciences, 78(18), 2081\u20132087. https:\/\/doi.org\/10.1016\/j.lfs.2005.12.007 .","journal-title":"Life Sciences"},{"issue":"12","key":"9701_CR68","doi-asserted-by":"publisher","first-page":"11680","DOI":"10.1074\/jbc.M310369200","volume":"279","author":"NR Jana","year":"2004","unstructured":"Jana, N. R., Dikshit, P., Goswami, A., & Nukina, N. (2004). Inhibition of proteasomal function by curcumin induces apoptosis through mitochondrial pathway. The Journal of Biological Chemistry, 279(12), 11680\u201311685. https:\/\/doi.org\/10.1074\/jbc.M310369200 .","journal-title":"The Journal of Biological Chemistry"},{"issue":"14","key":"9701_CR69","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.2174\/09298673113206660135","volume":"21","author":"N Hasima","year":"2014","unstructured":"Hasima, N., & Aggarwal, B. B. (2014). Targeting proteasomal pathways by dietary curcumin for cancer prevention and treatment. Current Medicinal Chemistry, 21(14), 1583\u20131594.","journal-title":"Current Medicinal Chemistry"},{"issue":"18","key":"9701_CR70","doi-asserted-by":"publisher","first-page":"7283","DOI":"10.1158\/0008-5472.CAN-07-6246","volume":"68","author":"V Milacic","year":"2008","unstructured":"Milacic, V., Banerjee, S., Landis-Piwowar, K. R., Sarkar, F. H., Majumdar, A. P., & Dou, Q. P. (2008). Curcumin inhibits the proteasome activity in human colon cancer cells in vitro and in vivo. Cancer Research, 68(18), 7283\u20137292. https:\/\/doi.org\/10.1158\/0008-5472.CAN-07-6246 .","journal-title":"Cancer Research"},{"issue":"2","key":"9701_CR71","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1124\/mol.62.2.351","volume":"62","author":"JE Mullally","year":"2002","unstructured":"Mullally, J. E., & Fitzpatrick, F. A. (2002). Pharmacophore model for novel inhibitors of ubiquitin isopeptidases that induce p53-independent cell death. Molecular Pharmacology, 62(2), 351\u2013358.","journal-title":"Molecular Pharmacology"},{"issue":"8","key":"9701_CR72","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1158\/1535-7163.MCT-12-1057","volume":"12","author":"B Zhou","year":"2013","unstructured":"Zhou, B., Zuo, Y., Li, B., Wang, H., Liu, H., Wang, X., et al. (2013). Deubiquitinase inhibition of 19S regulatory particles by 4-arylidene curcumin analog AC17 causes NF-kappaB inhibition and p53 reactivation in human lung cancer cells. Molecular Cancer Therapeutics, 12(8), 1381\u20131392. https:\/\/doi.org\/10.1158\/1535-7163.MCT-12-1057 .","journal-title":"Molecular Cancer Therapeutics"},{"issue":"5","key":"9701_CR73","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1182\/blood-2013-05-500033","volume":"123","author":"Z Tian","year":"2014","unstructured":"Tian, Z., D'Arcy, P., Wang, X., Ray, A., Tai, Y. T., Hu, Y., et al. (2014). A novel small molecule inhibitor of deubiquitylating enzyme USP14 and UCHL5 induces apoptosis in multiple myeloma and overcomes bortezomib resistance. Blood, 123(5), 706\u2013716. https:\/\/doi.org\/10.1182\/blood-2013-05-500033 .","journal-title":"Blood"},{"issue":"6","key":"9701_CR74","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1124\/mol.113.091322","volume":"85","author":"X Wang","year":"2014","unstructured":"Wang, X., Stafford, W., Mazurkiewicz, M., Fryknas, M., Brjnic, S., Zhang, X., et al. (2014). The 19S Deubiquitinase inhibitor b-AP15 is enriched in cells and elicits rapid commitment to cell death. Molecular Pharmacology, 85(6), 932\u2013945. https:\/\/doi.org\/10.1124\/mol.113.091322 .","journal-title":"Molecular Pharmacology"},{"issue":"12","key":"9701_CR75","doi-asserted-by":"publisher","first-page":"3174","DOI":"10.1158\/1078-0432.CCR-13-2658","volume":"20","author":"K Coughlin","year":"2014","unstructured":"Coughlin, K., Anchoori, R., Iizuka, Y., Meints, J., MacNeill, L., Vogel, R. I., et al. (2014). Small-molecule RA-9 inhibits proteasome-associated DUBs and ovarian cancer in vitro and in vivo via exacerbating unfolded protein responses. Clinical Cancer Research, 20(12), 3174\u20133186. https:\/\/doi.org\/10.1158\/1078-0432.CCR-13-2658 .","journal-title":"Clinical Cancer Research"},{"issue":"9","key":"9701_CR76","doi-asserted-by":"publisher","first-page":"1804","DOI":"10.4161\/cc.20174","volume":"11","author":"OA Issaenko","year":"2012","unstructured":"Issaenko, O. A., & Amerik, A. Y. (2012). Chalcone-based small-molecule inhibitors attenuate malignant phenotype via targeting deubiquitinating enzymes. Cell Cycle, 11(9), 1804\u20131817. https:\/\/doi.org\/10.4161\/cc.20174 .","journal-title":"Cell Cycle"},{"issue":"17","key":"9701_CR77","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.1089\/ars.2013.5322","volume":"21","author":"S Brnjic","year":"2014","unstructured":"Brnjic, S., Mazurkiewicz, M., Fryknas, M., Sun, C., Zhang, X., Larsson, R., et al. (2014). Induction of tumor cell apoptosis by a proteasome deubiquitinase inhibitor is associated with oxidative stress. Antioxidants & Redox Signaling, 21(17), 2271\u20132285. https:\/\/doi.org\/10.1089\/ars.2013.5322 .","journal-title":"Antioxidants & Redox Signaling"},{"issue":"5","key":"9701_CR78","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1111\/cbdd.12571","volume":"86","author":"X Wang","year":"2015","unstructured":"Wang, X., D'Arcy, P., Caulfield, T. R., Paulus, A., Chitta, K., Mohanty, C., et al. (2015). Synthesis and evaluation of derivatives of the proteasome deubiquitinase inhibitor b-AP15. Chemical Biology & Drug Design, 86(5), 1036\u20131048. https:\/\/doi.org\/10.1111\/cbdd.12571 .","journal-title":"Chemical Biology & Drug Design"},{"key":"9701_CR79","doi-asserted-by":"publisher","first-page":"26979","DOI":"10.1038\/srep26979","volume":"6","author":"X Wang","year":"2016","unstructured":"Wang, X., Mazurkiewicz, M., Hillert, E. K., Olofsson, M. H., Pierrou, S., Hillertz, P., et al. (2016). The proteasome deubiquitinase inhibitor VLX1570 shows selectivity for ubiquitin-specific protease-14 and induces apoptosis of multiple myeloma cells. Scientific Reports, 6, 26979. https:\/\/doi.org\/10.1038\/srep26979 .","journal-title":"Scientific Reports"},{"issue":"5","key":"9701_CR80","doi-asserted-by":"publisher","first-page":"R110 003871","DOI":"10.1074\/mcp.R110.003871","volume":"10","author":"MJ Lee","year":"2011","unstructured":"Lee, M. J., Lee, B. H., Hanna, J., King, R. W., & Finley, D. (2011). Trimming of ubiquitin chains by proteasome-associated deubiquitinating enzymes. Molecular & Cellular Proteomics, 10(5), R110 003871. https:\/\/doi.org\/10.1074\/mcp.R110.003871 .","journal-title":"Molecular & Cellular Proteomics"},{"issue":"6","key":"9701_CR81","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1016\/j.bbadis.2017.03.017","volume":"1863","author":"MJ Kiprowska","year":"2017","unstructured":"Kiprowska, M. J., Stepanova, A., Todaro, D. R., Galkin, A., Haas, A., Wilson, S. M., et al. (2017). Neurotoxic mechanisms by which the USP14 inhibitor IU1 depletes ubiquitinated proteins and Tau in rat cerebral cortical neurons: relevance to Alzheimer\u2019s disease. Biochimica et Biophysica Acta, 1863(6), 1157\u20131170. https:\/\/doi.org\/10.1016\/j.bbadis.2017.03.017 .","journal-title":"Biochimica et Biophysica Acta"},{"issue":"5","key":"9701_CR82","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1111\/jnc.13941","volume":"140","author":"JW Min","year":"2017","unstructured":"Min, J. W., Lu, L., Freeling, J. L., Martin, D. S., & Wang, H. (2017). USP14 inhibitor attenuates cerebral ischemia\/reperfusion-induced neuronal injury in mice. Journal of Neurochemistry, 140(5), 826\u2013833. https:\/\/doi.org\/10.1111\/jnc.13941 .","journal-title":"Journal of Neurochemistry"},{"issue":"5","key":"9701_CR83","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1038\/nchembio.2326","volume":"13","author":"J Li","year":"2017","unstructured":"Li, J., Yakushi, T., Parlati, F., Mackinnon, A. L., Perez, C., Ma, Y., et al. (2017). Capzimin is a potent and specific inhibitor of proteasome isopeptidase Rpn11. Nature Chemical Biology, 13(5), 486\u2013493. https:\/\/doi.org\/10.1038\/nchembio.2326 .","journal-title":"Nature Chemical Biology"},{"key":"9701_CR84","doi-asserted-by":"publisher","unstructured":"Lauinger, L., Li, J., Shostak, A., Cemel, I. A., Ha, N., Zhang, Y., et al. (2017). Thiolutin is a zinc chelator that inhibits the Rpn11 and other JAMM metalloproteases. Nature Chemical Biology. https:\/\/doi.org\/10.1038\/nchembio.2370 .","DOI":"10.1038\/nchembio.2370"},{"issue":"14","key":"9701_CR85","doi-asserted-by":"publisher","first-page":"3445","DOI":"10.1039\/c0dt01743d","volume":"40","author":"M Rouffet","year":"2011","unstructured":"Rouffet, M., & Cohen, S. M. (2011). Emerging trends in metalloprotein inhibition. Dalton Transactions, 40(14), 3445\u20133454. https:\/\/doi.org\/10.1039\/c0dt01743d .","journal-title":"Dalton Transactions"},{"issue":"7","key":"9701_CR86","doi-asserted-by":"crossref","first-page":"777","DOI":"10.2174\/138161209787582183","volume":"15","author":"D Chen","year":"2009","unstructured":"Chen, D., Milacic, V., Frezza, M., & Dou, Q. P. (2009). Metal complexes, their cellular targets and potential for cancer therapy. Current Pharmaceutical Design, 15(7), 777\u2013791.","journal-title":"Current Pharmaceutical Design"},{"key":"9701_CR87","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/j.ejphar.2014.07.025","volume":"740","author":"S Dasari","year":"2014","unstructured":"Dasari, S., & Tchounwou, P. B. (2014). Cisplatin in cancer therapy: molecular mechanisms of action. European Journal of Pharmacology, 740, 364\u2013378. https:\/\/doi.org\/10.1016\/j.ejphar.2014.07.025 .","journal-title":"European Journal of Pharmacology"},{"issue":"6550","key":"9701_CR88","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1038\/377649a0","volume":"377","author":"PM Takahara","year":"1995","unstructured":"Takahara, P. M., Rosenzweig, A. C., Frederick, C. A., & Lippard, S. J. (1995). Crystal structure of double-stranded DNA containing the major adduct of the anticancer drug cisplatin. Nature, 377(6550), 649\u2013652. https:\/\/doi.org\/10.1038\/377649a0 .","journal-title":"Nature"},{"issue":"5","key":"9701_CR89","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1002\/med.10038","volume":"23","author":"YP Ho","year":"2003","unstructured":"Ho, Y. P., Au-Yeung, S. C., & To, K. K. (2003). Platinum-based anticancer agents: Innovative design strategies and biological perspectives. Medicinal Research Reviews, 23(5), 633\u2013655. https:\/\/doi.org\/10.1002\/med.10038 .","journal-title":"Medicinal Research Reviews"},{"issue":"2","key":"9701_CR90","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.cbpa.2007.11.013","volume":"12","author":"PC Bruijnincx","year":"2008","unstructured":"Bruijnincx, P. C., & Sadler, P. J. (2008). New trends for metal complexes with anticancer activity. Current Opinion in Chemical Biology, 12(2), 197\u2013206. https:\/\/doi.org\/10.1016\/j.cbpa.2007.11.013 .","journal-title":"Current Opinion in Chemical Biology"},{"issue":"5","key":"9701_CR91","first-page":"1183","volume":"69","author":"KS Raju","year":"1982","unstructured":"Raju, K. S., Alessandri, G., Ziche, M., & Gullino, P. M. (1982). Ceruloplasmin, copper ions, and angiogenesis. Journal of the National Cancer Institute, 69(5), 1183\u20131188.","journal-title":"Journal of the National Cancer Institute"},{"issue":"3","key":"9701_CR92","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1002\/(SICI)1097-4644(19980601)69:3<326::AID-JCB10>3.0.CO;2-A","volume":"69","author":"GF Hu","year":"1998","unstructured":"Hu, G. F. (1998). Copper stimulates proliferation of human endothelial cells under culture. Journal of Cellular Biochemistry, 69(3), 326\u2013335.","journal-title":"Journal of Cellular Biochemistry"},{"issue":"11","key":"9701_CR93","first-page":"5390","volume":"44","author":"SL Rizk","year":"1984","unstructured":"Rizk, S. L., & Sky-Peck, H. H. (1984). Comparison between concentrations of trace elements in normal and neoplastic human breast tissue. Cancer Research, 44(11), 5390\u20135394.","journal-title":"Cancer Research"},{"issue":"4","key":"9701_CR94","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1159\/000226722","volume":"46","author":"M Diez","year":"1989","unstructured":"Diez, M., Arroyo, M., Cerdan, F. J., Munoz, M., Martin, M. A., & Balibrea, J. L. (1989). Serum and tissue trace metal levels in lung cancer. Oncology, 46(4), 230\u2013234.","journal-title":"Oncology"},{"issue":"1","key":"9701_CR95","first-page":"108","volume":"47","author":"SB Nayak","year":"2003","unstructured":"Nayak, S. B., Bhat, V. R., Upadhyay, D., & Udupa, S. L. (2003). Copper and ceruloplasmin status in serum of prostate and colon cancer patients. Indian Journal of Physiology and Pharmacology, 47(1), 108\u2013110.","journal-title":"Indian Journal of Physiology and Pharmacology"},{"issue":"17","key":"9701_CR96","first-page":"4854","volume":"62","author":"Q Pan","year":"2002","unstructured":"Pan, Q., Kleer, C. G., van Golen, K. L., Irani, J., Bottema, K. M., Bias, C., et al. (2002). Copper deficiency induced by tetrathiomolybdate suppresses tumor growth and angiogenesis. Cancer Research, 62(17), 4854\u20134859.","journal-title":"Cancer Research"},{"issue":"21","key":"9701_CR97","doi-asserted-by":"publisher","first-page":"10425","DOI":"10.1158\/0008-5472.CAN-06-2126","volume":"66","author":"D Chen","year":"2006","unstructured":"Chen, D., Cui, Q. C., Yang, H., & Dou, Q. P. (2006). Disulfiram, a clinically used anti-alcoholism drug and copper-binding agent, induces apoptotic cell death in breast cancer cultures and xenografts via inhibition of the proteasome activity. Cancer Research, 66(21), 10425\u201310433. https:\/\/doi.org\/10.1158\/0008-5472.CAN-06-2126 .","journal-title":"Cancer Research"},{"issue":"4","key":"9701_CR98","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1158\/0008-5472.CAN-06-3546","volume":"67","author":"D Chen","year":"2007","unstructured":"Chen, D., Cui, Q. C., Yang, H., Barrea, R. A., Sarkar, F. H., Sheng, S., et al. (2007). Clioquinol, a therapeutic agent for Alzheimer\u2019s disease, has proteasome-inhibitory, androgen receptor-suppressing, apoptosis-inducing, and antitumor activities in human prostate cancer cells and xenografts. Cancer Research, 67(4), 1636\u20131644. https:\/\/doi.org\/10.1158\/0008-5472.CAN-06-3546 .","journal-title":"Cancer Research"},{"issue":"6","key":"9701_CR99","doi-asserted-by":"publisher","first-page":"R897","DOI":"10.1186\/bcr1322","volume":"7","author":"KG Daniel","year":"2005","unstructured":"Daniel, K. G., Chen, D., Orlu, S., Cui, Q. C., Miller, F. R., & Dou, Q. P. (2005). Clioquinol and pyrrolidine dithiocarbamate complex with copper to form proteasome inhibitors and apoptosis inducers in human breast cancer cells. Breast Cancer Research, 7(6), R897\u2013R908. https:\/\/doi.org\/10.1186\/bcr1322 .","journal-title":"Breast Cancer Research"},{"issue":"2","key":"9701_CR100","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1007\/s00775-009-0594-5","volume":"15","author":"S Zhai","year":"2010","unstructured":"Zhai, S., Yang, L., Cui, Q. C., Sun, Y., Dou, Q. P., & Yan, B. (2010). Tumor cellular proteasome inhibition and growth suppression by 8-hydroxyquinoline and clioquinol requires their capabilities to bind copper and transport copper into cells. Journal of Biological Inorganic Chemistry, 15(2), 259\u2013269. https:\/\/doi.org\/10.1007\/s00775-009-0594-5 .","journal-title":"Journal of Biological Inorganic Chemistry"},{"issue":"6","key":"9701_CR101","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1016\/j.bcp.2003.10.031","volume":"67","author":"KG Daniel","year":"2004","unstructured":"Daniel, K. G., Gupta, P., Harbach, R. H., Guida, W. C., & Dou, Q. P. (2004). Organic copper complexes as a new class of proteasome inhibitors and apoptosis inducers in human cancer cells. Biochemical Pharmacology, 67(6), 1139\u20131151. https:\/\/doi.org\/10.1016\/j.bcp.2003.10.031 .","journal-title":"Biochemical Pharmacology"},{"issue":"24","key":"9701_CR102","doi-asserted-by":"publisher","first-page":"7242","DOI":"10.1021\/jm060712l","volume":"49","author":"S Adsule","year":"2006","unstructured":"Adsule, S., Barve, V., Chen, D., Ahmed, F., Dou, Q. P., Padhye, S., et al. (2006). Novel Schiff base copper complexes of quinoline-2 carboxaldehyde as proteasome inhibitors in human prostate cancer cells. Journal of Medicinal Chemistry, 49(24), 7242\u20137246. https:\/\/doi.org\/10.1021\/jm060712l .","journal-title":"Journal of Medicinal Chemistry"},{"issue":"8","key":"9701_CR103","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1007\/s00775-012-0940-x","volume":"17","author":"Z Zhang","year":"2012","unstructured":"Zhang, Z., Bi, C., Schmitt, S. M., Fan, Y., Dong, L., Zuo, J., et al. (2012). 1,10-Phenanthroline promotes copper complexes into tumor cells and induces apoptosis by inhibiting the proteasome activity. Journal of Biological Inorganic Chemistry, 17(8), 1257\u20131267. https:\/\/doi.org\/10.1007\/s00775-012-0940-x .","journal-title":"Journal of Biological Inorganic Chemistry"},{"issue":"36","key":"9701_CR104","doi-asserted-by":"publisher","first-page":"24306","DOI":"10.1074\/jbc.M109.026583","volume":"284","author":"S Tardito","year":"2009","unstructured":"Tardito, S., Isella, C., Medico, E., Marchio, L., Bevilacqua, E., Hatzoglou, M., et al. (2009). The thioxotriazole copper(II) complex A0 induces endoplasmic reticulum stress and paraptotic death in human cancer cells. The Journal of Biological Chemistry, 284(36), 24306\u201324319. https:\/\/doi.org\/10.1074\/jbc.M109.026583 .","journal-title":"The Journal of Biological Chemistry"},{"issue":"12","key":"9701_CR105","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.2174\/138955712802762068","volume":"12","author":"Z Skrott","year":"2012","unstructured":"Skrott, Z., & Cvek, B. (2012). Diethyldithiocarbamate complex with copper: the mechanism of action in cancer cells. Mini Reviews in Medicinal Chemistry, 12(12), 1184\u20131192.","journal-title":"Mini Reviews in Medicinal Chemistry"},{"issue":"1","key":"9701_CR106","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1080\/08927010903216564","volume":"26","author":"KV Thomas","year":"2010","unstructured":"Thomas, K. V., & Brooks, S. (2010). The environmental fate and effects of antifouling paint biocides. Biofouling, 26(1), 73\u201388. https:\/\/doi.org\/10.1080\/08927010903216564 .","journal-title":"Biofouling"},{"key":"9701_CR107","doi-asserted-by":"publisher","first-page":"5240","DOI":"10.1038\/srep05240","volume":"4","author":"N Liu","year":"2014","unstructured":"Liu, N., Liu, C., Li, X., Liao, S., Song, W., Yang, C., et al. (2014). A novel proteasome inhibitor suppresses tumor growth via targeting both 19S proteasome deubiquitinases and 20S proteolytic peptidases. Scientific Reports, 4, 5240. https:\/\/doi.org\/10.1038\/srep05240 .","journal-title":"Scientific Reports"},{"issue":"4","key":"9701_CR108","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1016\/j.cbpc.2009.01.003","volume":"149","author":"K Mochida","year":"2009","unstructured":"Mochida, K., Ito, K., Harino, H., Tanaka, H., Onduka, T., Kakuno, A., et al. (2009). Inhibition of acetylcholinesterase by metabolites of copper pyrithione (CuPT) and its possible involvement in vertebral deformity of a CuPT-exposed marine teleostean fish. Comp Biochem Physiol C Toxicol Pharmacol, 149(4), 624\u2013630. https:\/\/doi.org\/10.1016\/j.cbpc.2009.01.003 .","journal-title":"Comp Biochem Physiol C Toxicol Pharmacol"},{"issue":"3","key":"9701_CR109","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1016\/j.chemosphere.2010.09.074","volume":"82","author":"K Mochida","year":"2011","unstructured":"Mochida, K., Amano, H., Onduka, T., Kakuno, A., & Fujii, K. (2011). Toxicity and metabolism of copper pyrithione and its degradation product, 2,2\u2032-dipyridyldisulfide in a marine polychaete. Chemosphere, 82(3), 390\u2013397. https:\/\/doi.org\/10.1016\/j.chemosphere.2010.09.074 .","journal-title":"Chemosphere"},{"issue":"24","key":"9701_CR110","doi-asserted-by":"publisher","first-page":"8786","DOI":"10.1039\/c5cs00132c","volume":"44","author":"T Zou","year":"2015","unstructured":"Zou, T., Lum, C. T., Lok, C. N., Zhang, J. J., & Che, C. M. (2015). Chemical biology of anticancer gold(III) and gold(I) complexes. Chemical Society Reviews, 44(24), 8786\u20138801. https:\/\/doi.org\/10.1039\/c5cs00132c .","journal-title":"Chemical Society Reviews"},{"issue":"21","key":"9701_CR111","doi-asserted-by":"publisher","first-page":"10478","DOI":"10.1158\/0008-5472.CAN-06-3017","volume":"66","author":"V Milacic","year":"2006","unstructured":"Milacic, V., Chen, D., Ronconi, L., Landis-Piwowar, K. R., Fregona, D., & Dou, Q. P. (2006). A novel anticancer gold(III) dithiocarbamate compound inhibits the activity of a purified 20S proteasome and 26S proteasome in human breast cancer cell cultures and xenografts. Cancer Research, 66(21), 10478\u201310486. https:\/\/doi.org\/10.1158\/0008-5472.CAN-06-3017 .","journal-title":"Cancer Research"},{"issue":"11\u201312","key":"9701_CR112","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1016\/j.ccr.2009.01.032","volume":"253","author":"V Milacic","year":"2009","unstructured":"Milacic, V., & Dou, Q. P. (2009). The tumor proteasome as a novel target for gold(III) complexes: implications for breast cancer therapy. Coordination Chemistry Reviews, 253(11\u201312), 1649\u20131660. https:\/\/doi.org\/10.1016\/j.ccr.2009.01.032 .","journal-title":"Coordination Chemistry Reviews"},{"issue":"1","key":"9701_CR113","doi-asserted-by":"publisher","first-page":"e84248","DOI":"10.1371\/journal.pone.0084248","volume":"9","author":"C Nardon","year":"2014","unstructured":"Nardon, C., Schmitt, S. M., Yang, H., Zuo, J., Fregona, D., & Dou, Q. P. (2014). Gold(III)-dithiocarbamato peptidomimetics in the forefront of the targeted anticancer therapy: preclinical studies against human breast neoplasia. PLoS One, 9(1), e84248. https:\/\/doi.org\/10.1371\/journal.pone.0084248 .","journal-title":"PLoS One"},{"issue":"6","key":"9701_CR114","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1002\/1097-0142(197912)44:6<1965::AID-CNCR2820440602>3.0.CO;2-6","volume":"44","author":"TM Simon","year":"1979","unstructured":"Simon, T. M., Kunishima, D. H., Vibert, G. J., & Lorber, A. (1979). Inhibitory effects of a new oral gold compound on HeLa cells. Cancer, 44(6), 1965.","journal-title":"Cancer"},{"issue":"1","key":"9701_CR115","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s40268-015-0083-y","volume":"15","author":"C Roder","year":"2015","unstructured":"Roder, C., & Thomson, M. J. (2015). Auranofin: repurposing an old drug for a golden new age. Drugs R D, 15(1), 13\u201320. https:\/\/doi.org\/10.1007\/s40268-015-0083-y .","journal-title":"Drugs R D"},{"issue":"6","key":"9701_CR116","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1016\/j.freeradbiomed.2006.12.021","volume":"42","author":"C Marzano","year":"2007","unstructured":"Marzano, C., Gandin, V., Folda, A., Scutari, G., Bindoli, A., & Rigobello, M. P. (2007). Inhibition of thioredoxin reductase by auranofin induces apoptosis in cisplatin-resistant human ovarian cancer cells. Free Radical Biology & Medicine, 42(6), 872\u2013881. https:\/\/doi.org\/10.1016\/j.freeradbiomed.2006.12.021 .","journal-title":"Free Radical Biology & Medicine"},{"issue":"9","key":"9701_CR117","doi-asserted-by":"publisher","first-page":"2520","DOI":"10.1158\/0008-5472.CAN-13-2033","volume":"74","author":"W Fiskus","year":"2014","unstructured":"Fiskus, W., Saba, N., Shen, M., Ghias, M., Liu, J., Gupta, S. D., et al. (2014). Auranofin induces lethal oxidative and endoplasmic reticulum stress and exerts potent preclinical activity against chronic lymphocytic leukemia. Cancer Research, 74(9), 2520\u20132532. https:\/\/doi.org\/10.1158\/0008-5472.CAN-13-2033 .","journal-title":"Cancer Research"},{"issue":"14","key":"9701_CR118","doi-asserted-by":"publisher","first-page":"5453","DOI":"10.18632\/oncotarget.2113","volume":"5","author":"N Liu","year":"2014","unstructured":"Liu, N., Li, X., Huang, H., Zhao, C., Liao, S., Yang, C., et al. (2014). Clinically used antirheumatic agent auranofin is a proteasomal deubiquitinase inhibitor and inhibits tumor growth. Oncotarget, 5(14), 5453\u20135471. 10.18632\/oncotarget.2113 .","journal-title":"Oncotarget"},{"issue":"1","key":"9701_CR119","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1158\/1078-0432.CCR-13-1063","volume":"20","author":"X Shi","year":"2014","unstructured":"Shi, X., Chen, X., Li, X., Lan, X., Zhao, C., Liu, S., et al. (2014). Gambogic acid induces apoptosis in imatinib-resistant chronic myeloid leukemia cells via inducing proteasome inhibition and caspase-dependent Bcr-Abl downregulation. Clinical Cancer Research, 20(1), 151\u2013163. https:\/\/doi.org\/10.1158\/1078-0432.CCR-13-1063 .","journal-title":"Clinical Cancer Research"},{"issue":"8","key":"9701_CR120","first-page":"853","volume":"88","author":"S Gatto","year":"2003","unstructured":"Gatto, S., Scappini, B., Pham, L., Onida, F., Milella, M., Ball, G., et al. (2003). The proteasome inhibitor PS-341 inhibits growth and induces apoptosis in Bcr\/Abl-positive cell lines sensitive and resistant to imatinib mesylate. Haematologica, 88(8), 853\u2013863.","journal-title":"Haematologica"},{"issue":"22","key":"9701_CR121","doi-asserted-by":"publisher","first-page":"3276","DOI":"10.1038\/onc.2010.81","volume":"29","author":"MP Albero","year":"2010","unstructured":"Albero, M. P., Vaquer, J. M., Andreu, E. J., Villanueva, J. J., Franch, L., Ivorra, C., et al. (2010). Bortezomib decreases Rb phosphorylation and induces caspase-dependent apoptosis in Imatinib-sensitive and -resistant Bcr-Abl1-expressing cells. Oncogene, 29(22), 3276\u20133286. https:\/\/doi.org\/10.1038\/onc.2010.81 .","journal-title":"Oncogene"},{"key":"9701_CR122","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/BF01630378","volume":"8","author":"PC Nowell","year":"1962","unstructured":"Nowell, P. C. (1962). The minute chromosome (Phl) in chronic granulocytic leukemia. Blut, 8, 65\u201366.","journal-title":"Blut"},{"issue":"7","key":"9701_CR123","first-page":"2049","volume":"60","author":"MW Deininger","year":"2000","unstructured":"Deininger, M. W., Vieira, S., Mendiola, R., Schultheis, B., Goldman, J. M., & Melo, J. V. (2000). BCR-ABL tyrosine kinase activity regulates the expression of multiple genes implicated in the pathogenesis of chronic myeloid leukemia. Cancer Research, 60(7), 2049\u20132055.","journal-title":"Cancer Research"},{"key":"9701_CR124","doi-asserted-by":"publisher","unstructured":"Shah, N. P. (2005). Loss of response to imatinib: mechanisms and management. Hematology Am Soc Hematol Educ Program, 183\u2013187. https:\/\/doi.org\/10.1182\/asheducation-2005.1.183 .","DOI":"10.1182\/asheducation-2005.1.183"},{"issue":"19","key":"9701_CR125","doi-asserted-by":"publisher","first-page":"9118","DOI":"10.18632\/oncotarget.2361","volume":"5","author":"X Chen","year":"2014","unstructured":"Chen, X., Shi, X., Zhao, C., Li, X., Lan, X., Liu, S., et al. (2014). Anti-rheumatic agent auranofin induced apoptosis in chronic myeloid leukemia cells resistant to imatinib through both Bcr\/Abl-dependent and -independent mechanisms. Oncotarget, 5(19), 9118\u20139132. 10.18632\/oncotarget.2361 .","journal-title":"Oncotarget"},{"key":"9701_CR126","doi-asserted-by":"publisher","unstructured":"Chen, X., Shi, X., Wang, X., & Liu, J. (2014). Novel use of old drug: anti-rheumatic agent auranofin overcomes imatinib-resistance of chronic myeloid leukemia cells. Cancer Cell Microenviron, 1(6). 10.14800\/ccm.415 .","DOI":"10.14800\/ccm.415"},{"issue":"3","key":"9701_CR127","doi-asserted-by":"publisher","first-page":"2796","DOI":"10.18632\/oncotarget.6425","volume":"7","author":"H Huang","year":"2016","unstructured":"Huang, H., Liao, Y., Liu, N., Hua, X., Cai, J., Yang, C., et al. (2016). Two clinical drugs deubiquitinase inhibitor auranofin and aldehyde dehydrogenase inhibitor disulfiram trigger synergistic anti-tumor effects in vitro and in vivo. Oncotarget, 7(3), 2796\u20132808. 10.18632\/oncotarget.6425 .","journal-title":"Oncotarget"},{"issue":"4","key":"9701_CR128","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1046\/j.1467-2494.2003.00183.x","volume":"25","author":"P Bailey","year":"2003","unstructured":"Bailey, P., Arrowsmith, C., Darling, K., Dexter, J., Eklund, J., Lane, A., et al. (2003). A double-blind randomized vehicle-controlled clinical trial investigating the effect of ZnPTO dose on the scalp vs. antidandruff efficacy and antimycotic activity. International Journal of Cosmetic Science, 25(4), 183\u2013188. https:\/\/doi.org\/10.1046\/j.1467-2494.2003.00183.x .","journal-title":"International Journal of Cosmetic Science"},{"issue":"1","key":"9701_CR129","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.ajic.2004.07.012","volume":"33","author":"E Guthery","year":"2005","unstructured":"Guthery, E., Seal, L. A., & Anderson, E. L. (2005). Zinc pyrithione in alcohol-based products for skin antisepsis: persistence of antimicrobial effects. American Journal of Infection Control, 33(1), 15\u201322. https:\/\/doi.org\/10.1016\/j.ajic.2004.07.012 .","journal-title":"American Journal of Infection Control"},{"issue":"6","key":"9701_CR130","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1159\/000066452","volume":"15","author":"C Pierard-Franchimont","year":"2002","unstructured":"Pierard-Franchimont, C., Goffin, V., Decroix, J., & Pierard, G. E. (2002). A multicenter randomized trial of ketoconazole 2% and zinc pyrithione 1% shampoos in severe dandruff and seborrheic dermatitis. Skin Pharmacology and Applied Skin Physiology, 15(6), 434\u2013441 doi:66452.","journal-title":"Skin Pharmacology and Applied Skin Physiology"},{"issue":"13","key":"9701_CR131","doi-asserted-by":"publisher","first-page":"5318","DOI":"10.1158\/0008-5472.CAN-08-0601","volume":"68","author":"D Magda","year":"2008","unstructured":"Magda, D., Lecane, P., Wang, Z., Hu, W., Thiemann, P., Ma, X., et al. (2008). Synthesis and anticancer properties of water-soluble zinc ionophores. Cancer Research, 68(13), 5318\u20135325. https:\/\/doi.org\/10.1158\/0008-5472.CAN-08-0601 .","journal-title":"Cancer Research"},{"issue":"2","key":"9701_CR132","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1007\/s10534-010-9302-8","volume":"23","author":"E Rudolf","year":"2010","unstructured":"Rudolf, E., & Cervinka, M. (2010). Zinc pyrithione induces cellular stress signaling and apoptosis in Hep-2 cervical tumor cells: the role of mitochondria and lysosomes. Biometals, 23(2), 339\u2013354. https:\/\/doi.org\/10.1007\/s10534-010-9302-8 .","journal-title":"Biometals"},{"issue":"8","key":"9701_CR133","doi-asserted-by":"publisher","first-page":"13942","DOI":"10.18632\/oncotarget.14572","volume":"8","author":"C Zhao","year":"2017","unstructured":"Zhao, C., Chen, X., Yang, C., Zang, D., Lan, X., Liao, S., et al. (2017). Repurposing an antidandruff agent to treating cancer: zinc pyrithione inhibits tumor growth via targeting proteasome-associated deubiquitinases. Oncotarget, 8(8), 13942\u201313956. 10.18632\/oncotarget.14572 .","journal-title":"Oncotarget"},{"key":"9701_CR134","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.bcp.2016.06.019","volume":"116","author":"C Zhao","year":"2016","unstructured":"Zhao, C., Chen, X., Zang, D., Lan, X., Liao, S., Yang, C., et al. (2016). Platinum-containing compound platinum pyrithione is stronger and safer than cisplatin in cancer therapy. Biochemical Pharmacology, 116, 22\u201338. https:\/\/doi.org\/10.1016\/j.bcp.2016.06.019 .","journal-title":"Biochemical Pharmacology"},{"issue":"12","key":"9701_CR135","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.1016\/j.jinorgbio.2009.08.009","volume":"103","author":"P Marques-Gallego","year":"2009","unstructured":"Marques-Gallego, P., Contaldi, S., den Dulk, H., Monari, M., Brouwer, J., Jaehde, U., et al. (2009). Relevance of the leaving group for antitumor activity of new platinum(II) compounds containing anthracene derivatives as a carrier ligand. Journal of Inorganic Biochemistry, 103(12), 1602\u20131608. https:\/\/doi.org\/10.1016\/j.jinorgbio.2009.08.009 .","journal-title":"Journal of Inorganic Biochemistry"},{"issue":"45","key":"9701_CR136","doi-asserted-by":"publisher","first-page":"5916","DOI":"10.1038\/onc.2016.114","volume":"35","author":"C Zhao","year":"2016","unstructured":"Zhao, C., Chen, X., Zang, D., Lan, X., Liao, S., Yang, C., et al. (2016). A novel nickel complex works as a proteasomal deubiquitinase inhibitor for cancer therapy. Oncogene, 35(45), 5916\u20135927. https:\/\/doi.org\/10.1038\/onc.2016.114 .","journal-title":"Oncogene"},{"issue":"1","key":"9701_CR137","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1186\/s13045-016-0359-x","volume":"9","author":"X Lan","year":"2016","unstructured":"Lan, X., Zhao, C., Chen, X., Zhang, P., Zang, D., Wu, J., et al. (2016). Nickel pyrithione induces apoptosis in chronic myeloid leukemia cells resistant to imatinib via both Bcr\/Abl-dependent and Bcr\/Abl-independent mechanisms. Journal of Hematology & Oncology, 9(1), 129. https:\/\/doi.org\/10.1186\/s13045-016-0359-x .","journal-title":"Journal of Hematology & Oncology"},{"issue":"6","key":"9701_CR138","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1007\/s00216-012-6450-4","volume":"405","author":"M Groessl","year":"2013","unstructured":"Groessl, M., & Hartinger, C. G. (2013). Anticancer metallodrug research analytically painting the \u201comics\u201d picture--current developments and future trends. Analytical and Bioanalytical Chemistry, 405(6), 1791\u20131808. https:\/\/doi.org\/10.1007\/s00216-012-6450-4 .","journal-title":"Analytical and Bioanalytical Chemistry"},{"issue":"8","key":"9701_CR139","doi-asserted-by":"publisher","first-page":"4540","DOI":"10.1021\/cr400460s","volume":"114","author":"KD Mjos","year":"2014","unstructured":"Mjos, K. D., & Orvig, C. (2014). Metallodrugs in medicinal inorganic chemistry. Chemical Reviews, 114(8), 4540\u20134563. https:\/\/doi.org\/10.1021\/cr400460s .","journal-title":"Chemical Reviews"},{"key":"9701_CR140","doi-asserted-by":"publisher","first-page":"10702","DOI":"10.1039\/b912708a","volume":"48","author":"C Sanchez-Cano","year":"2009","unstructured":"Sanchez-Cano, C., & Hannon, M. J. (2009). Novel and emerging approaches for the delivery of metallo-drugs. Dalton Transactions, 48, 10702\u201310711. https:\/\/doi.org\/10.1039\/b912708a .","journal-title":"Dalton Transactions"},{"issue":"7","key":"9701_CR141","doi-asserted-by":"publisher","first-page":"5654","DOI":"10.1021\/nn403220e","volume":"7","author":"NP Barry","year":"2013","unstructured":"Barry, N. P., & Sadler, P. J. (2013). Challenges for metals in medicine: how nanotechnology may help to shape the future. ACS Nano, 7(7), 5654\u20135659. https:\/\/doi.org\/10.1021\/nn403220e .","journal-title":"ACS Nano"},{"issue":"5","key":"9701_CR142","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1021\/jm201480u","volume":"55","author":"MN Kouodom","year":"2012","unstructured":"Kouodom, M. N., Ronconi, L., Celegato, M., Nardon, C., Marchio, L., Dou, Q. P., et al. (2012). Toward the selective delivery of chemotherapeutics into tumor cells by targeting peptide transporters: tailored gold-based anticancer peptidomimetics. Journal of Medicinal Chemistry, 55(5), 2212\u20132226. https:\/\/doi.org\/10.1021\/jm201480u .","journal-title":"Journal of Medicinal Chemistry"}],"container-title":["Cancer and Metastasis Reviews"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10555-017-9701-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10555-017-9701-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10555-017-9701-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,19]],"date-time":"2020-10-19T23:01:45Z","timestamp":1603148505000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10555-017-9701-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10,16]]},"references-count":142,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["9701"],"URL":"https:\/\/doi.org\/10.1007\/s10555-017-9701-1","relation":{},"ISSN":["0167-7659","1573-7233"],"issn-type":[{"value":"0167-7659","type":"print"},{"value":"1573-7233","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,10,16]]}}}